Ranjan Kumar Acharyya

10PUBLICATIONS
16CO-AUTHORS
Separation technologiesCheminformatics and quantitative structure-activity relationshipsMedical molecular engineering of nucleic acids and proteinsChemical engineering designMedical devices
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jul 05, 2026
Discovery of SD-2301 as a Highly Potent and Selective PROTAC STAT3 Degrader Capable of Achieving Complete Tumor Regression with Single Administration.

|Mar 23, 2026
Discovery of SD-965 as a Potent, Selective, and Efficacious STAT3 PROTAC Degrader.

Dimin Wu, Haibin Zhou, Longchuan Bai

|Jan 10, 2026
An Update on Clinically Advanced PROTAC Degraders and Their Synthesis.

Ranjan Kumar Acharyya, Yugandhar Kothapalli, Suresh Yarlagadda

|Jun 13, 2025
MD-4251: A First-in-Class Oral MDM2 Degrader Inducing Complete Tumor Regression with Single-Dose Administration.

Ranjan Kumar Acharyya, Liyue Huang, Angelo Aguilar

|May 14, 2025
Discovery and Characterization of PVTX-321 as a Potent and Orally Bioavailable Estrogen Receptor Degrader for ER+/HER2- Breast Cancer.

Guozhang Xu, Courtney G Havens, Qiaolin Deng

|Apr 08, 2025
Correction to "Discovery of ERD-1233 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader for the Treatment of ER+ Human Breast Cancer".

Ranjan Kumar Acharyya, Rohan Kalyan Rej, Biao Hu

Pageof 2

Frequent Collaborators

8 joint publications

Shaomeng Wang

7 joint publications

Rohan Kalyan Rej

7 joint publications

Duxin Sun

4 joint publications

Biao Hu